Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Cozzi Lepri

Showing results (131-140 of 227) with videos related to

Pageof 23
Sort By:
The Journal of Infectious Diseases|October 24, 2007
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patientsFrancesca Ceccherini-Silberstein, Alessandro Cozzi-Lepri, Lidia Ruiz, et al.
Antiviral Therapy|November 13, 2004
Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systemsAndrea De Luca, Alessandro Cozzi-Lepri, Carlo-Federico Perno, et al.
Open Forum Infectious Diseases|January 9, 2018
Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015Dominic E Dwyer, Ruth Lynfield, Marcelo H Losso, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 30, 2026
Did the COVID-19 pandemic shift the landscape of late HIV diagnosis?Giulia Micheli, Annalisa Mondi, Ashley Roen, et al.
The Journal of Infectious Diseases|June 3, 2006
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loadsAlessandro Cozzi-Lepri, Andrea De Luca, Andrew N Phillips, et al.
Viruses|January 8, 2025
Probability of Starting Two-Drug Regimen (2DR) vs. Three-Drug Regimen (3DR) in ART-Naïve and ART-Experienced Person with HIV (PWH) Across the First Wave of COVID-19 PandemicAlessandra Vergori, Nicola Gianotti, Alessandro Tavelli, et al.
Scientific Reports|August 18, 2025
CT changes in a randomized trial comparing early therapies in an outpatient population at high risk of severe COVID19 diseaseIlaria Mastrorosa, Alessandro Cozzi-Lepri, Giulia Matusali, et al.
Travel Medicine and Infectious Disease|April 3, 2022
Prevalence of Chagas disease and strongyloidiasis among HIV-infected Latin American immigrants in Italy - The CHILI studyPaola Rodari, Francesca Tamarozzi, Stefano Tais, et al.
Microorganisms|August 14, 2020
Epidemiology and Outcomes of Bloodstream Infections in HIV-Patients during a 13-Year PeriodE Franceschini, Antonella Santoro, Marianna Menozzi, et al.
Journal of Global Antimicrobial Resistance|January 30, 2025
Assessing the utilization of HIV genotype resistance testing: Insight from Italian Infectious Diseases UnitsAndrea De Vito, Antonia Bezenchek, Rossana Scutari, et al.
Pageof 23

Showing results (131-140 of 227) with videos related to

Sort By:
Pageof 23
The Journal of Infectious Diseases|October 24, 2007
Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue-based regimens in antiretroviral therapy (ART)-naive and ART-experienced patientsFrancesca Ceccherini-Silberstein, Alessandro Cozzi-Lepri, Lidia Ruiz, et al.
Antiviral Therapy|November 13, 2004
Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systemsAndrea De Luca, Alessandro Cozzi-Lepri, Carlo-Federico Perno, et al.
Open Forum Infectious Diseases|January 9, 2018
Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009-2015Dominic E Dwyer, Ruth Lynfield, Marcelo H Losso, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|January 30, 2026
Did the COVID-19 pandemic shift the landscape of late HIV diagnosis?Giulia Micheli, Annalisa Mondi, Ashley Roen, et al.
The Journal of Infectious Diseases|June 3, 2006
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loadsAlessandro Cozzi-Lepri, Andrea De Luca, Andrew N Phillips, et al.
Viruses|January 8, 2025
Probability of Starting Two-Drug Regimen (2DR) vs. Three-Drug Regimen (3DR) in ART-Naïve and ART-Experienced Person with HIV (PWH) Across the First Wave of COVID-19 PandemicAlessandra Vergori, Nicola Gianotti, Alessandro Tavelli, et al.
Scientific Reports|August 18, 2025
CT changes in a randomized trial comparing early therapies in an outpatient population at high risk of severe COVID19 diseaseIlaria Mastrorosa, Alessandro Cozzi-Lepri, Giulia Matusali, et al.
Travel Medicine and Infectious Disease|April 3, 2022
Prevalence of Chagas disease and strongyloidiasis among HIV-infected Latin American immigrants in Italy - The CHILI studyPaola Rodari, Francesca Tamarozzi, Stefano Tais, et al.
Microorganisms|August 14, 2020
Epidemiology and Outcomes of Bloodstream Infections in HIV-Patients during a 13-Year PeriodE Franceschini, Antonella Santoro, Marianna Menozzi, et al.
Journal of Global Antimicrobial Resistance|January 30, 2025
Assessing the utilization of HIV genotype resistance testing: Insight from Italian Infectious Diseases UnitsAndrea De Vito, Antonia Bezenchek, Rossana Scutari, et al.
Pageof 23